Medically reviewed by Brigid Dwyer, MD Key Takeaways Disease-modifying therapies slow down the progression of multiple ...

March 31, 2010 — A blood test may soon be able to identify which patients with multiple sclerosis will and will not respond to beta interferon. Only a reported two-thirds of patients with ...

NEW YORK (Reuters Health) - Early treatment of multiple sclerosis (MS) patients with interferon beta-1b therapy may help slow down the onset of disability, according to a report in this week's issue ...

October 24, 2011 (Amsterdam, the Netherlands) — The full results of a phase 3 trial directly comparing alemtuzumab (Lemtrada, Genzyme) with interferon-beta-1a (Rebif, EMD Serono/Pfizer) show a ...

Medically reviewed by Lindsay Cook, PharmD Key Takeaways MS medications can help slow the disease and manage symptoms.

Disease activity despite interferon predicts poor MS outcomes In relapsing-remitting MS, disease activity after treatment with interferon (IFN)β-1a linked to poor long-term outcomes. HealthDay News — ...

medwireNews: The DECIDE study shows that 4-weekly daclizumab high-yield process (HYP) reduces disease activity in patients with relapsing–remitting multiple sclerosis (MS) more effectively than weekly ...